Multi-dimensional analysis shows PDK4's potential as a biomarker and target for immunotherapy in cancer, suggesting a path for personalized treatment.
PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: